Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 18th Preview)
-
Capped US hospital scrutiny on CAR-T intestinal toxicity
Mount Sinai researchers reported that BCMA-directed CAR-T cells can persist in the gut and trigger severe intestinal inflammation in a subset of patients, linking a key toxicity mechanism to where the engineered cells traffic after infusion. The work underscores that CAR-T efficacy gains have come with distinct, compartment-specific safety questions that may be missed without targeted tissue tracking.
-
Diasome outlines Phase 3 readiness for hepatocyte-targeted HDV-insulin in type 1 diabetes
Diasome said its HDV-Insulin program for type 1 diabetes is moving into final Phase 3 planning after what it called promising data, targeting hepatocyte delivery through its hepatocyte-directed vesicle lipid nanoparticle platform. The approach is designed to concentrate insulin (and related payloads) toward portal-hepatic regions to mimic endogenous release patterns and improve hepatic bioavailability.
-
Liquidia settles with United Therapeutics, narrows Yutrepia label
Liquidia’s stock rebounded after the company reached a settlement with United Therapeutics that ended six lawsuits tied to Yutrepia (treprostinil) patent and antitrust claims. As part of the deal, Liquidia agreed to pay $380.7 million to settle antitrust litigation and to remove pulmonary hypertension associated with interstitial lung disease (PH-ILD) from the product’s label, while keeping Yutrepia for pulmonary arterial hypertension.
-
EHR-driven latent TB screening under California’s mandate
A UC San Diego team reported that an EHR algorithm built for California’s new latent TB screening law drove a surge in testing but left the care cascade incomplete. Implementation prompted 547 additional blood tests, while data showed that fewer than one in four eligible patients who tested positive began treatment.
-
AI on CT scans to forecast bladder cancer recurrence
Researchers in China developed an explainable deep learning model that analyzes contrast-enhanced CT scans to predict whether non-muscle-invasive bladder cancer will recur within two years after surgery. The work targets decision support in recurrence risk stratification by using interpretability techniques to connect imaging features to predicted outcomes.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.